Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | PAM | P19021 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820326 | 0.98 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL3505591 | 0.98 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL3503231 | 0.98 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL8847123 | 0.98 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL19709434 | 0.98 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL3503023 | 0.98 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL29288177 | 0.98 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL6728610 | 0.98 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL1683937 | 0.98 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL12742199 | 0.96 | DGKA (0.68) | DGKADNM1PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107705878-A | A kind of carbon electric slurry and preparation method thereof | 武汉配斯特科技有限公司 | 2018-02-16 | — | — | CN | claimed |
| WO-2024161862-A1 | PHOTOSENSITIVE COMPOSITION, CURED PRODUCT, DISPLAY DEVICE, AND METHOD FOR PRODUCING CURED PRODUCT | 東レ株式会社 | 2024-08-08 | — | — | WO | disclosed |
| CN-109788760-A | Antimicrobial photoreactive composition comprising organic and inorganic more knot composite materials | 艾克森实验室有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109714968-A | POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | 艾克森实验室有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109682508-A | A kind of sensitive ink material and pliable pressure thin film sensor and preparation method thereof | 贝骨新材料科技（上海）有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-107705878-A | A kind of carbon electric slurry and preparation method thereof | 武汉配斯特科技有限公司 | 2018-02-16 | — | — | CN | disclosed |
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| WO-2017100461-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | SOLSTICE BIOLOGICS, LTD. (IE) | 2017-06-15 | — | — | WO | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3156077-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2017-04-19 | — | — | EP | disclosed |
| EP-0839812-A1 | Preparation of benzylthiazolidine derivatives | Sankyo Company Limited (JP) | 1998-05-06 | — | — | EP | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
| EP-0382213-B1 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMA CO LTD (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-5387596-A | Treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0454501-A2 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | Sankyo Company Limited (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-5053548-A | Containing hydroxy substituents; nervous system disorders | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0382213-A2 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4882452-A | CRYSTALLIZATION, ANTITUMOR | ASTA PHARMA AKTEINGESELLSCHAFT (DE) | 1989-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | DGKA 3823/4885DNM1 3484/4885MGLL 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.